Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(12 sites)
United States
Joe DiMaggio Cycstic Fibrosis & Pulmonary Center, Hollywood, Florida AdventHealth Medical Group Pulmonology at Orlando Ridgewood, Orlando, Florida Altasciences Clinical Kansas, Overland Park, Kansas Kentucky Children's Hospital, Lexington, Kentucky Boston Children's Hospital, Boston, Massachusetts